My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Siemens drops after dull Q2 financial performance
May 11,2017

The result was announced at fag end of the days trading session yesterday, 10 May 2017, when the stock rose 1% to settle at Rs 1,460.90.

Meanwhile, the S&P BSE Sensex was up 104.27 points, or 0.34% to 30,352.44.

On the BSE, 46,000 shares were traded in the counter so far, compared with average daily volumes of 27,416 shares in the past one quarter. The stock had hit a high of Rs 1,443.80 and a low of Rs 1,404 so far during the day. The stock hit a 52-week high of Rs 1,470 on 10 May 2017. The stock hit a 52-week low of Rs 1,011 on 9 November 2016.

The large-cap company has equity capital of Rs 71.22 crore. Face value per share is Rs 2.

Siemens registered 45% increase in new orders from continuing operations to Rs 7948 crore in the first half of calendar year 2017 (CY 2017) over CY 2016.

Sunil Mathur, Managing Director and Chief Executive Officer, Siemens said that all divisions of the company have performed well. With digital solutions, the company is supporting customers in finding solutions to problems that are foremost on their minds. Public sector business is growing well with focus by the Government on the transmission and distribution of power as also on modernizing the Indian railways.

Siemens focuses on the areas of electrification, automation and digitalization. It is one of the leading producers of technologies for combined cycle turbines for power generation; power transmission and distribution solutions; infrastructure solutions for Smart Cities and transportation; automation and software solutions for industry, and also supplier of healthcare equipments. As on 31 March 2017, Siemens AG held 75% stake in Siemens.

Powered by Capital Market - Live News

Hindalco Industries jumps after good Q4 earnings from Novelis
May 11,2017

Meanwhile, the S&P BSE Sensex was up 109.35 points, or 0.36% to 30,357.52.

On the BSE, 9.22 lakh shares were traded in the counter so far, compared with average daily volumes of 11.29 lakh shares in the past one quarter. The stock had hit a high of Rs 195.80 and a low of Rs 192.20 so far during the day. The stock hit a 52-week high of Rs 203.85 on 2 May 2017. The stock hit a 52-week low of Rs 83.60 on 24 May 2016.

The stock had underperformed the market over the past one month till 10 May 2017, falling 4.78% compared with 1.54% rise in the Sensex. The scrip had also underperformed the market in past one quarter, rising 1.82% as against Sensexs 6.77% rise.

The large-cap company has equity capital of Rs 224.34 crore. Face value per share is Re 1.

Novelis Inc, an overseas subsidiary of Hindalco Industries, announced 46% jump in net income at $73 million in Q4 March 2017. Net sales increased 9% to $2.6 billion for the fourth quarter of fiscal 2017, driven by higher average aluminum prices and increased shipments of higher conversion premium products, including a 26% increase in automotive shipments.

Meanwhile, Novelis Inc entered into a joint venture agreement with Japans Kobe Steel. The joint venture, to be named Ulsan Aluminum, will be formed by Novelis selling Kobe Steel 50% of its ownership interest in its Ulsan, South Korea facility for $315 million. Through the venture, Novelis and Kobe Steel will jointly own and operate the Ulsan facility, with each company remaining responsible for its metal supply and commercial relationships. The joint venture transaction is expected to close in September 2017, subject to customary closing conditions.

By entering into this joint venture, Novelis will better utilize its rolling capacity at Ulsan, which will continue to focus on automotive and specialty sheet in order to meet the increasing demand for lightweight rolled aluminum products across Asia. Partnering with another world-class manufacturing company will allow Novelis to drive operational efficiencies and process enhancements. As a result, Novelis Ulsan facility, along with its Yeongju facility in South Korea and its Changzhou facility in China, will be better positioned to deliver innovative, value-added products and services to customers. The transaction will generate cash proceeds to enhance Novelis strategic flexibility and reduce its net debt.

Hindalco Industries reported a net profit of Rs 320.56 crore in Q3 December 2016 as against net loss of Rs 32.75 crore in Q3 December 2015. Net sales rose 15.2% to Rs 9226.04 crore in Q3 December 2016 over Q3 December 2015.

Hindalco Industries, metals flagship company of the Aditya Birla Group, is the industry leader in aluminium and copper.

Powered by Capital Market - Live News

Ashoka Buildcon gains after winning contracts
May 11,2017

The announcement was made during trading hours today, 11 May 2017.

Meanwhile, the S&P BSE Sensex was up 96.38 points, or 0.32% to 30,344.55.

On the BSE, 42,000 shares were traded in the counter so far, compared with average daily volumes of 6.28 lakh shares in the past one quarter. The stock had hit a high of Rs 217.40 and a low of Rs 207.10 so far during the day. The stock hit a record high of Rs 231.55 on 7 April 2017. The stock hit a 52-week low of Rs 127 on 7 June 2016.

The stock had underperformed the market over the past one month till 10 May 2017, falling 1.17% compared with 1.54% rise in the Sensex. The scrip had also underperformed the market in past one quarter, rising 6.37% as against Sensexs 6.77% rise.

The mid-cap company has equity capital of Rs 93.57 crore. Face value per share is Rs 5.

Ashoka Buildcon informs that the company is in receipt of letters of intent from Jharkhand Bijli Vitran Nigam (JBVNL), for the projects viz. execution of urban electrification works for Ranchi and Medininagar towns in Jharkhand and electric supply to areas covering 12 towns in Jharkahand under Integrated Power Development Scheme (IPDS). The aggregate value of the above work is Rs 282.73 crore.

IPDS is the flagship program of Government of India, Ministry of Power and funded by Power Finance Corporation.

Ashoka Buildcons net profit spurted 114.7% to Rs 42.70 crore on 17.2% increase in net sales to Rs 517.74 crore in Q3 December 2016 over Q3 December 2015.

Ashoka Buildcon is a leading highway concessionaire and engineering, procurement and construction (EPC) company.

Powered by Capital Market - Live News

SML Isuzu in reverse gear after weak Q4 result
May 11,2017

The result was announced after market hours yesterday, 10 May 2017.

Meanwhile, the S&P BSE Sensex was up 110.84 points or 0.37% at 30,359.01. The S&P BSE Mid-Cap index was up 82.13 points, or 0.52% at 15,743.78.

On the BSE, 4,731 shares were traded on the counter so far as against the average daily volumes of 6,369 shares in the past one quarter. The stock had hit a high of Rs 1,355 and a low of Rs 1,315 so far during the day. The stock had hit a 52-week high of Rs 1,433.85 on 31 August 2016 and a 52-week low of Rs 891.45 on 24 May 2016.

The small-cap company has equity capital of Rs 14.47 crore. Face value per share is Rs 10.

SML Isuzu is a commercial vehicle manufacturer. Sumitomo Corporation, Japan and Isuzu Motors, Japan respectively held 43.96% and 15% stake in SML Isuzu (as per the shareholding pattern as on 31 March 2017).

Powered by Capital Market - Live News

HCL Tech slips after Q4 results
May 11,2017

Meanwhile, the S&P BSE Sensex was up 73.33 points, or 0.24% to 30,321.50.

On the BSE, 1.02 lakh shares were traded in the counter so far, compared with average daily volumes of 2.20 lakh shares in the past one quarter. The stock had hit a high of Rs 858.20 and a low of Rs 840 so far during the day. The stock hit a 52-week high of Rs 889.65 on 31 March 2017. The stock hit a 52-week low of Rs 706.50 on 11 May 2016.

The stock had underperformed the market over the past one month till 10 May 2017, rising 1.04% compared with 1.54% rise in the Sensex. The scrip had also underperformed the market in past one quarter, rising 2.79% as against Sensexs 6.77% rise.

The large-cap IT company has equity capital of Rs 285.39 crore. Face value per share is Rs 2.

On a consolidated basis, HCL Technologies net income rose 15% to Rs 8457 crore on 14.2% increase in revenue to Rs 46723 crore in the year ended March 2017 over the year ended December 2016.

In its guidance, HCL Technologies said that in the financial year ending March 2018 (FY18), its revenues are expected to grow between 10.5% to 12.5% in constant currency. The above constant currency guidance translates to 9.9% to 11.9% in USD terms based on 31 March 2017 rates.

Operating margin (EBIT) in FY18 is expected in range from 19.5% to 20.5%. The operating margin guidance assumes USD-INR currency rate of $1=Rs 65.50 and other currencies at FY17 average exchange rates.

HCL Technologies is a global IT services company.

Powered by Capital Market - Live News

Hero MotoCorp gains after Q4 results
May 11,2017

The result was announced after market hours yesterday, 10 May 2017.

Meanwhile, the S&P BSE Sensex was up 69.34 points, or 0.23% to 30,317.51.

On the BSE, 14,000 shares were traded in the counter so far, compared with average daily volumes of 43,259 shares in the past one quarter. The stock had hit a high of Rs 3,379.50 and a low of Rs 3,295.50 so far during the day. The stock hit a record high of Rs 3,739.90 on 8 September 2016. The stock hit a 52-week low of Rs 2,844.40 on 17 November 2016.

The stock had outperformed the market over the past one month till 10 May 2017, rising 3.78% compared with 1.54% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, rising 1.78% as against Sensexs 6.77% rise.

The large-cap two-wheeler major has equity capital of Rs 39.94 crore. Face value per share is Rs 2.

Hero MotoCorp said it took a proactive approach towards the launch of BS IV-compliant vehicles, and liquidated large BS III inventory, leading up to 29 March 2017. In the last two days of the month, the company took some tactical steps to assist its dealers and incentivise the customers with an objective to liquidate the remaining BS Ill stocks, resulting in a one-time impact to the margins of the fourth quarter.

EBITDA (earnings before interest, taxes, depreciation and amortization) margin stood at 12.79% in Q4 March 2017, lower than 14.66% in Q4 March 2016.

Hero MotoCorps retail sales have been outpacing wholesale numbers, as a result of which the company has now been able to maintain healthy dealer inventory. Meanwhile, input costs have been on an upward trend. To partially offset the commodity costs, Hero MotoCorp raised prices ranging from Rs 500 to Rs 2200 on some of the models, with effect from 1 May 2017.

Hero MotoCorp is the worlds largest manufacturer of two-wheelers.

Powered by Capital Market - Live News

Caplin Point scales record high after stellar Q4 outcome
May 11,2017

The result was announced after market hours yesterday, 10 May 2017.

Meanwhile, the S&P BSE Sensex was up 62.87 points or 0.21% at 30,311.04. The S&P BSE Mid-Cap index was up 95.51 points, or 0.64% at 15,045.05.

On BSE, so far 67,000 shares were traded in the counter as against average daily volume of 7,391 shares in the past one quarter. The stock hit a high of Rs 466.95 in intraday trade so far, which is a record high for the counter. The stock hit a low of Rs 430.80 so far during the day. The stock hit a 52-week low of Rs 184 on 12 May 2016.

The mid-cap company has equity capital of Rs 15.12 crore. Face value per share is Rs 2.

Caplin Points earnings before interest, taxation, depreciation and amortization (EBITDA) rose 116% to Rs 47.64 crore in Q4 March 2017 over Q4 March 2016. The companys EBITDA margin surged to 40% in Q4 March 2017 from 27% in Q4 March 2016.

Caplin Point on 8 May 2017 announced that the company has received the Establishment Inspection Report (EIR) from USFDA (United States Food and Drug Administration) for inspection carried out between 21 October 2016 to 27 October 2016, at its sterile injectable plant at Gummidopoondi, Tamil Nadu (TN).

Caplin Point Laboratories is a niche pharmaceutical company, catering predominantly to emerging markets of Latin America and Africa. The company caters to a complete range of finished dosage forms.

Powered by Capital Market - Live News

Zee in spotlight after stellar Q4 financial performance
May 10,2017

The result was announced during market hours today, 10 May 2017.

Meanwhile, the S&P BSE Sensex was up 325.51 points or 1.09% at 30,258.76.

On the BSE, 2.74 lakh shares were traded on the counter so far as against the average daily volumes of 82,892 shares in the past one quarter. The stock had hit a high of Rs 521.50 and a low of Rs 496.30 so far during the day. The stock had hit a 52-week high of Rs 588.80 on 3 October 2016 and a 52-week low of Rs 405 on 9 May 2016.

The large-cap company has equity capital of Rs 96.04 crore. Face value per share is Re 1.

Zee Entertainment Enterprises Q4 March 2017 consolidated net profit was boosted by an exceptional income of Rs 1223.44 crore on account of sale of Sports Broadcasting Business to Sony Pictures Network.

Advertising revenue for Q4 March 2017 was Rs 846.90 crore. Domestic advertising revenue grew by 8.1% to Rs 794.40 crore while international advertising revenue stood at Rs 52.50 crore.

Subscription revenue fell 6.1% to Rs 558 crore in Q4 March 2017 over Q4 March 2016 due to high base on account of catch-up revenues in Q4 March 2016. Domestic subscription revenue stood at Rs 455.40 crore while international subscription revenue stood at Rs 102.60 crore.

Earnings before interest, tax, depreciation and amortization (EBITDA) rose 14% to Rs 468.70 crore in Q4 March 2017 over Q4 March 2016. EBITDA margin stood at 30.7%.

Zee Entertainment Enterprises said that after a couple of quarters of weakness, advertising growth appears to be back on track. The GST roll-out could boost advertising spends as a part of potential tax savings might be reinvested. While there is uncertainty regarding the implementation of the new tariff regulation due to pending litigations, the company has published the prices of its channels and bouquets. The company is confident that with the strong competitive position of channels in every genre, it will be able to drive subscription business.

Zee Entertainment Enterprises is one of Indias leading television media and entertainment companies. The company and its affiliate companies have leading presence across the media value chain including television broadcasting, cable distribution, direct-to-home satellite services, digital media and print media amongst others.

Powered by Capital Market - Live News

Kotak Mahindra Bank gains after shareholders OK raising foreign investment limit
May 10,2017

The announcement was made after market hours yesterday, 9 May 2017.

Meanwhile, the S&P BSE Sensex was up 323.32 points, or 1.08% to 30,256.57.

On the BSE, 77,000 shares were traded in the counter so far, compared with average daily volumes of 6.72 lakh shares in the past one quarter. The stock had hit a high of Rs 929 so far during the day, which is also a record high for the counter. The stock had hit a low of Rs 912 so far during the day. The stock hit a 52-week low of Rs 692.40 on 24 May 2016.

The stock had outperformed the market over the past one month till 9 May 2017, rising 3.57% compared with 1.21% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 18.17% as against Sensexs 5.81% rise.

The large-cap company has equity capital of Rs 920.51 crore. Face value per share is Rs 5.

Kotak Mahindra Bank said that its shareholders approved increasing ceiling limit of Foreign Institutional Investors (FIIs) and Foreign Portfolio Investors (FPIs) holding in the bank to 49% from existing 42%. Shareholders also approved issuing 6.20 crore shares via American Depository Receipt (ADR) or Global Depository Receipt (GDR) or other permissible securities convertible into equity shares.

Kotak Mahindra Banks net profit rose 40.34% to Rs 976.48 crore on 9.85% rise in total income to Rs 5434.65 crore in Q4 March 2017 over Q4 March 2016.

Kotak Mahindra Bank is one of the leading private sector banks in India.

Powered by Capital Market - Live News

Volumes jump at Federal-Mogul Goetze (India) counter
May 10,2017

Federal-Mogul Goetze (India) clocked volume of 2.23 lakh shares by 14:55 IST on BSE, a 71.33-times surge over two-week average daily volume of 3,000 shares. The stock rose 1.01% to Rs 596.

Piramal Enterprises notched up volume of 3.54 lakh shares, a 31.37-fold surge over two-week average daily volume of 11,000 shares. The stock rose 1.04% to Rs 2,516.

Gujarat Mineral Development Corporation saw volume of 12.23 lakh shares, a 26.56-fold surge over two-week average daily volume of 46,000 shares. The stock jumped 6.06% to Rs 133.05. Gujarat Mineral Development Corporations net profit jumped 135.81% to Rs 90.01 crore on 42.42% rise in total income to Rs 553.36 crore in Q4 March 2017 over Q4 March 2016. The Q4 result was announced after market hours yesterday, 9 May 2017.

HSIL clocked volume of 1.53 lakh shares, a 26.41-fold surge over two-week average daily volume of 6,000 shares. The stock rose 0.6% to Rs 346.15.

Cyient saw volume of 1.60 lakh shares, a 20.11-fold rise over two-week average daily volume of 8,000 shares. The stock rose 1.05% to Rs 537.65.

Powered by Capital Market - Live News

Marksans Pharma in pink of health after UK MHRA approval
May 10,2017

The announcement was made during market hours today, 10 May 2017.

Meanwhile, the BSE Sensex was up 290.72 points, or 0.97%, to 30,223.97. The S&P BSE Small-Cap index was up 122.15 points, or 0.79% to 15,666.78

On the BSE, so far 37.51 lakh shares were traded in the counter, compared with average daily volumes of 10.68 lakh shares in the past one quarter. The stock had hit a high of Rs 56.25 and a low of Rs 48.20 so far during the day. The stock hit a 52-week high of Rs 58.30 on 6 October 2016. The stock hit a 52-week low of Rs 36.95 on 1 February 2017.

The stock had underperformed the market over the past one month till 9 May 2017, sliding 4.27% compared with 1.21% rise in the Sensex. The scrip also underperformed the market in past one quarter, declining 14.02% as against Sensexs 5.81% rise.

The small-cap company has equity capital of Rs 40.93 crore. Face value per share is Re 1.

It may be recalled that Marksans Pharma had announced on 20 February 2017, that its Goa plants inspection by UK MHRA from 14 February 2017 to 17 February 2017 was completed without any critical observations.

Marksans Pharmas consolidated net profit fell 37% to Rs 11.30 crore on 1% decrease in net sales to Rs 215.24 in Q3 December 2016 over Q3 December 2015.

Marksans Pharma is a global pharmaceutical company. It is engaged in research & development (R&D) and offers CRAMS (contract research and manufacturing services) to global pharmaceutical companies.

Powered by Capital Market - Live News

Biocon slips after USFDA observations
May 10,2017

Meanwhile, the S&P BSE Sensex was up 273.51 points, or 0.91% to 30,206.76.

On the BSE, 2.04 lakh shares were traded in the counter so far, compared with average daily volumes of 64,781 shares in the past one quarter. The stock had hit a high of Rs 1,037.05 and a low of Rs 984.25 so far during the day. The stock hit a 52-week high of Rs 1,188 on 25 April 2017. The stock hit a 52-week low of Rs 610.40 on 10 May 2016.

The stock had underperformed the market over the past one month till 9 May 2017, falling 5.17% compared with 1.21% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 4.07% as against Sensexs 5.81% rise.

The large-cap bio-pharmaceutical company has equity capital of Rs 100 crore. Face value per share is Rs 5.

Biocon said observations on form 483 is a standard outcome of any audit. The company has already responded to US Food and Drug Administration (USFDA) on all observations of the recent audit within stipulated timelines. As a policy, the company does not comment on any schedule or outcomes of regulatory inspections, unless it believes that there is a material impact. Biocon has a good track record of inspections by the USFDA, European regulators and other regulators from developed and emerging markets, the company added.

On a consolidated basis, net profit of Biocon declined 61.71% to Rs 127.50 crore on 1.53% decline in net sales to Rs 919.20 crore in Q4 March 2017 over Q4 March 2016.

Biocon is Indias largest and fully-integrated, innovation-led biopharmaceutical company.

Powered by Capital Market - Live News

Nelco declines after weak Q4 results
May 10,2017

The result was announced after market hours yesterday, 9 May 2017.

Meanwhile, the S&P BSE Sensex was up 242.13 points, or 0.81% at 30,175.38. The S&P BSE Small-cap index was up 108.89 points, 0.7% at 15,653.52.

On the BSE, 47,000 shares were traded on the counter so far as against the average daily volumes of 34,490 shares in the past one quarter. The stock had hit a high of Rs 88.80 and a low of Rs 85.70 so far during the day.

The stock had hit a 52-week high of Rs 109.70 on 8 June 2016 and a 52-week low of Rs 68.40 on 22 November 2016. The stock had outperformed the market over the past one month till 9 May 2017, advancing 8.61% compared with the Sensexs 0.76% rise. The scrip had also outperformed the market over the past one quarter advancing 8.81% as against the Sensexs 5.66% rise.

The small-cap company has equity capital of Rs 22.82 crore. Face value per share is Rs 10.

Nelco offers solutions in the areas of integrated security & surveillance, VSAT connectivity (Tatanet VSAT), managed services, satcom projects and meteorological solutions. The company offers a range of innovative and customized solutions for businesses and government institutions under one roof.

Powered by Capital Market - Live News

Marksans Pharma leads gainers on BSEs A group
May 10,2017

Marksans Pharma rose 13.81% at Rs 54.80. The stock topped the gainers in A group. On the BSE, 32.21 lakh shares were traded on the counter so far as against the average daily volumes of 4.74 lakh shares in the past two weeks.

Gujarat Mineral Development Corporation (GMDC) rose 7.33% at Rs 134.65. The stock was the second biggest gainer in A group. On the BSE, 10.84 lakh shares were traded on the counter so far as against the average daily volumes of 46,000 shares in the past two weeks.

Escorts rose 7.04% at Rs 642. The stock was the third biggest gainer in A group. On the BSE, 9.69 lakh shares were traded on the counter so far as against the average daily volumes of 2.19 lakh shares in the past two weeks.

CG Power and Industrial Solutions rose 5.33% at Rs 87.95. The stock was the fourth biggest gainer in A group. On the BSE, 12.38 lakh shares were traded on the counter so far as against the average daily volumes of 3.29 lakh shares in the past two weeks.

Bharti Airtel rose 4.80% at Rs 362.10. The stock was the fifth biggest gainer in A group. On the BSE, 7.57 lakh shares were traded on the counter so far as against the average daily volumes of 1.16 lakh shares in the past two weeks.

Powered by Capital Market - Live News

Bitter pill for AstraZeneca Pharma after reverse turnaround in Q4
May 10,2017

The result was announced after market hours yesterday, 9 May 2017.

Meanwhile, the S&P BSE Sensex was up 263.29 points, or 0.88%, to 30,196.54. The S&P BSE Small-Cap index was up 130.87 points, or 0.84% to 15,675.50

On the BSE, 7,662 shares were traded on the counter so far as against the average daily volumes of 6,031 shares in the past one quarter. The stock had hit a high of Rs 968 and a low of Rs 945 so far during the day. The stock had hit a 52-week high of Rs 1,151 on 9 May 2016 and a 52-week low of Rs 909 on 1 March 2017.

The stock had outperformed the market over the past one month till 9 May 2017, rising 2.76% compared with 1.21% rise in the Sensex. The scrip, however, underperformed the market in past one quarter, gaining 5.09% as against Sensexs 5.81% rise.

The small-cap company has equity capital of Rs 5 crore. Face value per share is Rs 2.

AstraZeneca Pharma Indias total income dropped 26.66% to Rs 118.01 crore in Q4 March 2017 over Q4 March 2016.

AstraZeneca Pharma India is engaged in the development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. AstraZeneca Pharmaceuticals AB holds 75% stake in AstraZeneca Pharma India (as per the shareholding pattern as on 31 March 2017).

Powered by Capital Market - Live News